Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus.
10.3343/alm.2012.32.3.201
- Author:
Yusun HWANG
1
;
Miae LEE
Author Information
1. Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea. miae@ewha.ac.kr
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Human papillomavirus;
Real-time PCR;
HPV type 16
- MeSH:
Adult;
Aged;
Cervix Uteri/pathology/virology;
DNA, Viral/analysis;
Female;
Genotype;
Human papillomavirus 16/genetics;
Human papillomavirus 18/genetics;
Humans;
Middle Aged;
Papillomaviridae/*genetics/isolation & purification;
Papillomavirus Infections/*diagnosis/pathology/virology;
Reagent Kits, Diagnostic;
Sensitivity and Specificity;
Young Adult
- From:Annals of Laboratory Medicine
2012;32(3):201-205
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We evaluated the performance of various commercial assays for the molecular detection of human papillomavirus (HPV); the recently developed AdvanSure HPV Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2). METHODS: All 3 tests were performed on 177 samples, and any sample that showed a discrepancy in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or sequencing. On the basis of these results, we obtained a consensus HPV result, and the performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection by using the 2 real-time PCR assays. RESULTS: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays; however, the results of the 3 assays with 37 samples were discrepant. Compared with the consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Abbott PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively. For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanSure PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA genotyping and/or sequencing. CONCLUSIONS: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can simultaneously differentiate type 16/18 HPV from other types.
